Advertisement

Supply Chain



Fagron agreed to pay $22.05 million to resolve allegations that its subsidiary, Freedom Pharmaceuticals, intentionally inflated average wholesale prices for its ingredients to increase reimbursements from federal healthcare programs.

Advertisement

Most Read

Advertisement
Advertisement